The drug was developed by Merck & Co. The phase III clinical trial for this medicine was stopped early after a review showed it was highly effective and had a good safety profile. Merck announced in 2014 that it would apply for regulatory approval in 2015.[4]
In 2016, Merck discontinued development of odanacatib and announced it would not seek regulatory approval after analysis discovered an increased risk of stroke.[5]
This drug was developed at Merck Frosst in Montreal.
Referencesedit
^(PDF). WHO Drug Information. 33 (3). World Health Organization: 239. 2008. Archived from the original (PDF) on 26 October 2013. Retrieved 11 November 2016.
^Le Gall C, Bonnelye E, Clézardin P (September 2008). "Cathepsin K inhibitors as treatment of bone metastasis". Current Opinion in Supportive and Palliative Care. 2 (3): 218–222. doi:10.1097/SPC.0b013e32830baea9. PMID 18685424. S2CID 5834581.
^Gauthier JY, Chauret N, Cromlish W, Desmarais S, Duong LT, Falgueyret JP, et al. (February 2008). "The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K". Bioorganic & Medicinal Chemistry Letters. 18 (3): 923–928. doi:10.1016/j.bmcl.2007.12.047. PMID 18226527.
^Pierson R (15 September 2014). "Merck osteoporosis drug passes trial, but side effects hover". Reuters. from the original on 2021-07-11.
^"Merck Provides Update on Odanacatib Development Program". Business Wire. 2016-09-02. from the original on 2016-09-03. Retrieved 2016-09-30.
odanacatib, codenamed, 0822, investigational, treatment, osteoporosis, bone, metastasis, inhibitor, cathepsin, enzyme, involved, bone, resorption, clinical, dataother, names, cyanocyclopropyl, fluoro, methyl, trifluoro, methanesulfonyl, biphenyl, ethyl, amino,. Odanacatib INN 1 codenamed MK 0822 is an investigational treatment for osteoporosis and bone metastasis 2 It is an inhibitor of cathepsin K 3 an enzyme involved in bone resorption OdanacatibClinical dataOther names 2S N 1 Cyanocyclopropyl 4 fluoro 4 methyl 2 1S 2 2 2 trifluoro 1 4 methanesulfonyl 1 1 biphenyl 4 yl ethyl amino pentanamideRoutes ofadministrationBy mouthATC codeNoneLegal statusLegal statusDevelopment terminatedIdentifiersIUPAC name N 1 Cyanocyclopropyl 4 fluoro N2 1S 2 2 2 trifluoro 1 4 methylsulfonyl biphenyl 4 yl ethyl L leucinamideCAS Number603139 19 1 YPubChem CID10152654IUPHAR BPS6478ChemSpider8328162 NUNIIN673F6W2VHKEGGD08955 NChEMBLChEMBL481611 NCompTox Dashboard EPA DTXSID40209075ECHA InfoCard100 207 747Chemical and physical dataFormulaC 25H 27F 4N 3O 3SMolar mass525 56 g mol 13D model JSmol Interactive imageSMILES CC C CC C O NC1 CC1 C N NC C2 CC C C C2 C3 CC C C C3 S O O C C F F F FInChI InChI 1S C25H27F4N3O3S c1 23 2 26 14 20 22 33 32 24 15 30 12 13 24 31 21 25 27 28 29 18 6 4 16 5 7 18 17 8 10 19 11 9 17 36 3 34 35 h4 11 20 21 31H 12 14H2 1 3H3 H 32 33 t20 21 m0 s1 NKey FWIVDMJALNEADT SFTDATJTSA N N N Y what is this verify The drug was developed by Merck amp Co The phase III clinical trial for this medicine was stopped early after a review showed it was highly effective and had a good safety profile Merck announced in 2014 that it would apply for regulatory approval in 2015 4 In 2016 Merck discontinued development of odanacatib and announced it would not seek regulatory approval after analysis discovered an increased risk of stroke 5 This drug was developed at Merck Frosst in Montreal References edit International Nonproprietary Names for Pharmaceutical Substances INN Recommended International Nonproprietary names List 60 PDF WHO Drug Information 33 3 World Health Organization 239 2008 Archived from the original PDF on 26 October 2013 Retrieved 11 November 2016 Le Gall C Bonnelye E Clezardin P September 2008 Cathepsin K inhibitors as treatment of bone metastasis Current Opinion in Supportive and Palliative Care 2 3 218 222 doi 10 1097 SPC 0b013e32830baea9 PMID 18685424 S2CID 5834581 Gauthier JY Chauret N Cromlish W Desmarais S Duong LT Falgueyret JP et al February 2008 The discovery of odanacatib MK 0822 a selective inhibitor of cathepsin K Bioorganic amp Medicinal Chemistry Letters 18 3 923 928 doi 10 1016 j bmcl 2007 12 047 PMID 18226527 Pierson R 15 September 2014 Merck osteoporosis drug passes trial but side effects hover Reuters Archived from the original on 2021 07 11 Merck Provides Update on Odanacatib Development Program Business Wire 2016 09 02 Archived from the original on 2016 09 03 Retrieved 2016 09 30 nbsp This drug article relating to the musculoskeletal system is a stub You can help Wikipedia by expanding it vte Retrieved from https en wikipedia org w index php title Odanacatib amp oldid 1182334998, wikipedia, wiki, book, books, library,
